Current Drug Targets
Volume 22, 17 Issues, 2021
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access
Editor's Choice
Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
, 2021; 22(17): 1986 - 2005Çağla Begüm Apaydın, Gözde Çınar and Gökçe Cihan-Üstündağ*
DOI: 10.2174/1389450122666210215112150
ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
, 2021; 22(16): 1832 - 1843Shuainan Li, Wenya Ma, Fan Yang, Yan Xu, Binbin Xu and Benzhi Cai*
DOI: 10.2174/1389450122666210319110320
GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
, 2021; 22(15): 1725 - 1737Dilipkumar Pal, Souvik Mukherjee, In-Ho Song and Satish B. Nimse*
DOI: 10.2174/1389450122666210114095307
Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
, 2021; 22(14): 1596 - 1617Cristina Daneri-Becerra, Sol M. Ciucci, Gisela Mazaira and Mario D. Galigniana*
DOI: 10.2174/1389450121999201230204320
Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
, 2021; 22(13): 1568 - 1576Ubaid Tariq, Shravan K. Uppulapu and Sanjay K. Banerjee*
DOI: 10.2174/1389450122666210224105430
Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes
, 2021; 22(12): 1424 - 1436Hafsa Qadri, Abdul H. Shah* and Manzoor Mir*
DOI: 10.2174/1389450121666201228123212
New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
, 2021; 22(11): 1198 - 1206Danishuddin, Naidu Subbarao*, Mohd Khan, Sultan Alouffi and Shahper Khan*
DOI: 10.2174/1389450122666210215111744
Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
, 2021; 22(10): 1149 - 1157Vivek K. Gupta*, Madhan K. Murthy and Shripad Patil
DOI: 10.2174/1389450121999201125201112
The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy
, 2021; 22(9): 1021 - 1033Michele Ghidini*, Nicola Fusco, Massimiliano Salati, Shelize Khakoo, Gianluca Tomasello, Fausto Petrelli, Dario Trapani and Angelica Petrillo
DOI: 10.2174/1389450122666210204204415
Cell-penetrating Peptide-mediated Nanovaccine Delivery
, 2021; 22(8): 896 - 912Jizong Jiang*
DOI: 10.2174/1389450122666210203193225
MiRNA, a New Treatment Strategy for Pulmonary Fibrosis
, 2021; 22(7): 793 - 802Yanhong Liu, Hongguang Nie*, Yan Ding, Yapeng Hou, Kejun Mao and Yong Cui
DOI: 10.2174/1874609813666200928141822
Progress in Detection of Insomnia Sleep Disorder: A Comprehensive Review
, 2021; 22(6): 672 - 684Md Belal Bin Heyat, Faijan Akhtar, M.A. Ansari, Asif Khan, Fahed Alkahtani, Haroon Khan* and Dakun Lai*
DOI: 10.2174/1389450121666201027125828
Antibiotic Potentiation of Natural Products: A Promising Target to Fight Pathogenic Bacteria
, 2021; 22(5): 555 - 572Nabeelah Bibi Sadeer and Mohamad Fawzi Mahomoodally*
DOI: 10.2174/1389450121666200924113740
Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
, 2021; 22(4): 399 - 419Selvakumar Muruganantham, Venkateshwaran Krishnaswami, Shanmugarathinam Alagarsamy and Ruckmani Kandasamy*
DOI: 10.2174/1389450121666201027125303
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
, 2021; 22(3): 254 - 281Cristina Vieira, Lucas Nery, Ludimila Martins, Luiz Jabour, Raphael Dias and Ana Cristina Simões e Silva*
DOI: 10.2174/1389450121666201020154033
Fibrotic Strictures in Crohn’s Disease: Mechanisms and Predictive Factors
, 2021; 22(2): 241 - 251Riccardo Mager, Giulia Roda, Mohammad Khaled Shalaby and Stefania Vetrano*
DOI: 10.2174/1389450121666201020160803
Neoadjuvant Chemotherapy Before Radical Cystectomy: Why We Must Adhere?
, 2021; 22(1): 14 - 21Beppe Calò*, Michele Marchioni, Francesca Sanguedolce, Ugo Giovanni Falagario, Marco Chirico, Giuseppe Carrieri and Luigi Cormio
DOI: 10.2174/1389450121666200802022150
The Activating Receptors of Natural Killer Cells and Their Inter-Switching Potentials
, 2020; 21(16): 1733 - 1751Adekunle Babajide Rowaiye, Titilayo Asala, Angus Nnamdi Oli*, Ikemefuna Chijioke Uzochukwu, Alex Akpa and Charles Okechukwu Esimone
DOI: 10.2174/1389450121666200910160929
Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma
, 2020; 21(15): 1606 - 1612Lei Cheng, Na Li, Xiao-ling Xu* and Wei-Min Mao*
DOI: 10.2174/1389450121666200719011234
Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far?
, 2020; 21(14): 1448 - 1455Haichao Wang, Chen Ye, Yaling Wu, Pengyu Yang, Chunqiu Chen, Zhanju Liu and Xiaolei Wang*
DOI: 10.2174/1389450121666200428102330
Editor-in-Chief
Francis J. Castellino
(14643 citations)
Dean Emeritus, College of Science,
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
(USA)
(14643 citations)
Dean Emeritus, College of Science,
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments⇨ Special Offers
For Authors
For Librarians & Readers
Quick Links
Journal History
Current Drug Targets Journal was launched in 2000. Dr. Francis J. Castellino serves as the Editor-in-Chief of the journal.
Webmaster Contact: info@benthamscience.net